{
  "label": "clinical_signal_03_ep_030",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:d598477d581c827ad0a45ee3009db9c9b11ea99e2336e981a4b51a9948e6576e",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:53.768035",
  "content": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 224\n- Active: 207\n- Screen Failures Cumulative: 78\n- Withdrawals Cumulative: 17\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 19\n- Site 05 Active: 19\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 19\n- Site 09 Active: 19\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 181.8\n- Statin Subgroup ALT (U/L) Median: 179.2\n- Statin Subgroup AST (U/L) Mean: 120.0\n- Statin Subgroup AST (U/L) Median: 119.0\n- Statin Subgroup Bilirubin (mg/dL) Mean: 3.1\n- Statin Subgroup Bilirubin (mg/dL) Median: 3.1\n- Statin Subgroup ALP (U/L) Mean: 57.0\n- Statin Subgroup ALP (U/L) Median: 75.7\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.96\n- Statin Subgroup Creatinine (mg/dL) Median: 0.96\n- Statin Subgroup BUN (mg/dL) Mean: 16.1\n- Statin Subgroup BUN (mg/dL) Median: 13.6\n- Statin Subgroup WBC (K) Mean: 7.8\n- Statin Subgroup WBC (K) Median: 6.3\n- Statin Subgroup Platelets (K) Mean: 219\n- Statin Subgroup Platelets (K) Median: 249\n- Non-Statin Subgroup N: 131\n- Non-Statin Subgroup ALT (U/L) Mean: 28.8\n- Non-Statin Subgroup ALT (U/L) Median: 26.9\n- Non-Statin Subgroup AST (U/L) Mean: 28.3\n- Non-Statin Subgroup AST (U/L) Median: 27.9\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.6\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.56\n- Non-Statin Subgroup ALP (U/L) Mean: 67.0\n- Non-Statin Subgroup ALP (U/L) Median: 64.9\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 1.02\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.97\n- Non-Statin Subgroup BUN (mg/dL) Mean: 14.1\n- Non-Statin Subgroup BUN (mg/dL) Median: 13.9\n- Non-Statin Subgroup WBC (K) Mean: 6.3\n- Non-Statin Subgroup WBC (K) Median: 7.9\n- Non-Statin Subgroup Platelets (K) Mean: 252\n- Non-Statin Subgroup Platelets (K) Median: 229\n\n### Adverse Events\n- AE ID: AE-0127, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0128, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0129, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0130, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0131, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0132, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 14\n- ACE Inhibitor Count: 29\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-062, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-063, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_03\n\n### Investigator Notes\n- Enrollment on track per protocol timeline\n- All CRFs current through prior visit cycle\n- Post-amendment statin subgroup n=8 (subjects who could not discontinue); hepatic monitoring frequency doubled\n\n### Events\n- Drug accountability audit at Site 05: no discrepancies\n- Investigator meeting minutes distributed\n- End-of-phase safety data compilation initiated for regulatory briefing\n\n### Notes\n- Week 30: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_030",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-09-23T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}